AWH: 3 New Board Members

“We are thrilled to welcome Stefanie, Jannie and Lynn to our Board of Directors,” said Dr. Veronica Jordan, Chairwoman of the Aspira Board of Directors . “Aspira has been through tremendous change this past year, and attracting top talent is a testament to the strength of the technology, strategy and potential as a company. We look forward to their guidance as we continue to grow and unlock the tremendous potential to improve the treatment pathway for all women.”

Nicole Sandford, President and Chief Executive Officer of Aspira Women’s Health said , “We warmly welcome our new members to the Aspira Board of Directors. Stefanie, Jannie and Lynn are very experienced and extraordinarily successful executives who bring a passion for improving women’s lives. I look forward to working closely with them as we move swiftly to the next level of growth.”

Ms Stefanie Cavanaugh joins the Board as a seasoned executive having been a senior financial executive for healthcare companies for over 30 years. Ms. Cavanaugh currently serves as Chief Financial Officer of Giving Home Health Care, an at-home healthcare services company.

Ms. Jannie Herchuck served in various roles at Deloitte & Touche since 1985 until her retirement as an audit partner in 2022. Ms. Herchuck most recently served on the Deloitte LLP board of directors leading strategic initiatives and practices.

Ms. Lynn O’Connor Vos is a healthcare CEO and Board Director with experience across product launches, global marketing , digital health, and M&A. She founded her own healthcare consultancy firm after having served as interim CEO of Modular Medical, Inc. She spent nearly 30 years as CEO of Greyhealth Group where she built a global healthcare communications firm and worked on launches for clients across the pharmaceutical, biotech, surgical and diagnostic sectors.

About Aspira Women’s Health Inc.
Aspira Women’s Health Inc. is transforming women’s gynecological health with the discovery, development, and commercialization of innovative testing options for women of all races and ethnicities, starting with ovarian cancer.

Our ovarian cancer risk assessment portfolio is marketed to healthcare providers as OvaSuite. OvaWatch SM is a non-invasive, blood-based test intended for use in the initial clinical assessment of ovarian cancer risk in women with benign or indeterminate adnexal masses for which surgical intervention may be either premature or unnecessary. With a negative predictive value (NPV) of 99%, OvaWatch allows physicians to confidently rule out ovarian cancer malignancy and choose the appropriate clinical management for the right patient at the right time. Ova1Plus ® combines our FDA-cleared products, Ova1 ® and Overa ® , to detect risk of ovarian malignancy in women with adnexal masses planned for surgery.

EndoCheck™, Aspira’s first-of-its-kind non-invasive diagnostic test for endometriosis, is currently in development. Visit our website for more information at www.aspirawh.com .